Sutro Biopharma Inc STRO.OQ STRO.O is expected to show a fall in quarterly revenue when it reports results on March 11 (estimated) for the period ending December 31 2025
The South San Francisco California-based company is expected to report a 43.7% decrease in revenue to $8.341 million from $14.81 million a year ago, according to the mean estimate from 10 analysts, based on LSEG data.
LSEG's mean analyst estimate for Sutro Biopharma Inc is for a loss of $4.34 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 3 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Sutro Biopharma Inc is $21.50, about 15% below its last closing price of $25.29
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -4.07 | -4.14 | -6.70 | Missed | -61.7 |
Jun. 30 2025 | -4.07 | -4.02 | -1.40 | Beat | 65.2 |
Mar. 31 2025 | -6.96 | -7.07 | -9.10 | Missed | -28.6 |
Dec. 31 2024 | -7.81 | -8.31 | -8.90 | Missed | -7.1 |
Sep. 30 2024 | -7.29 | -7.35 | -5.90 | Beat | 19.7 |
Jun. 30 2024 | -7.60 | -7.92 | -5.90 | Beat | 25.5 |
Mar. 31 2024 | -8.75 | -9.22 | -9.50 | Missed | -3 |
Dec. 31 2023 | -8.23 | 5.20 | Beat | 163.2 |
This summary was machine generated March 9 at 11:04 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments